July 21, 2019
Medtronic and Viz.ai Announce Partnership in Artificial Intelligence for Stroke Care
July 22, 2019—Medtronic and Viz.ai have announced a partnership and distribution agreement aimed at accelerating adoption of applied artificial intelligence (AI) for ischemic stroke detection and triage.
Based in San Francisco and Tel Aviv, Viz.ai has developed technology that uses AI/advanced deep learning to identify strokes occurring due to large vessel occlusion (LVO). The software interfaces with a hospital's CT scanners and can alert networked stroke specialists when a stroke is detected and send images to the team's smartphones.
“Viz.ai allows clinicians to receive an alert for suspected large vessel occlusions and the corresponding visual data,” commented Elad Levy, MD, in the companies' announcement. Dr. Levy is Chairman of the Department of Neurosurgery with the University at Buffalo's Jacobs School of Medicine and Biomedical Sciences and Medical Director of Neuroendovascular Services at the Gates Vascular Institute. “The combination of AI-powered alerts, mobile image viewing, and HIPAA-compliant communication facilitates synchronization of stroke care with great potential to impactfully reduce door-to-needle time and help an increased number of patients.”
“Viz.ai is fast emerging as the leader in artificial intelligence in stroke care," said Stacey Pugh, Vice President and General Manager of Medtronic’s Neurovascular business, in the announcement. "We are excited about this partnership because Viz.ai’s technology has the potential to significantly reduce the time it takes for patients suspected of LVO stroke to receive the care they need. Viz.ai’s software coupled with our network is going to increase access to needed therapies. It greatly complements our existing portfolio.”
Medtronic's current LVO portfolio includes the Solitaire revascularization platform.
“Medtronic is an innovative company focused on therapies that extend life and restore health,” added Chris Mansi, MD, who is a neurosurgeon and Cofounder and CEO of Viz.ai. “As the largest medical device company in the world, Medtronic is an ideal partner to help physicians access Viz.ai’s cutting-edge technology to ensure as many patients get the care they need as quickly as possible.”
Viz.ai gained FDA approval in February 2018 via the agency's de novo premarket review pathway.